Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of the CYP2D6 Haplotype Activity Scores Based on Metabolic Ratios of 4,700 Patients Treated With Three Different CYP2D6 Substrates.

Clinical pharmacology and therapeutics - 1 Sept 2021

Jukić Marin M, Smith Robert L, Molden Espen, Ingelman-Sundberg Magnus

Abstract excerpt

The metabolic activity of the polymorphic CYP2D6 enzyme is dependent on the CYP2D6 genotype; however, the guidelines for translating the genotype into phenotype, which are of relevance for adequate drug dose personalization, are ambiguous. In the present study, retrospective therapeutic drug monitoring data from 4,700 CYP2D6 genotyped patients treated with risperidone, venlafaxine, and/or aripiprazole were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Antipsychotic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Genotype

Share to Haplotypes

Share to Phenotype

Share to Risperidone

Share to Venlafaxine Hydrochloride

Source

Identifiers

PMID: 33792048
DOI: 10.1002/cpt.2246

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of the CYP2D6 Haplotype Activity Scores Based on Metabolic Ratios of 4,700 Patients Treated With Three Different CYP2D6 Substrates.PMID 33792048Read ↗

Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype.Semantic proximity Read ↗

Therapeutic Drug Monitoring of Psychotropics as a Diagnostic Tool for CYP2D6 Poor Metabolizer Phenotype.Semantic proximity Read ↗

Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype.Semantic proximity Read ↗

Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization.Semantic proximity Read ↗

Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients.Semantic proximity Read ↗

CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.Semantic proximity Read ↗

CYP2D6 pharmacogenomicsSemantic proximity Read ↗

Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study.Semantic proximity Read ↗

Complexities of CYP2D6 gene analysis and interpretation.Semantic proximity Read ↗

CYP2D6 polymorphisms and their influence on risperidone treatmentSemantic proximity Read ↗

Quantification of In Vivo Metabolic Activity of CYP2D6 Genotypes and Alleles Through Population Pharmacokinetic Analysis of Vortioxetine.Semantic proximity Read ↗

Improved Prediction of CYP2D6 Catalyzed Drug Metabolism by Taking Variant Substrate Specificities and Novel Polymorphic Haplotypes into Account.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.